The Food and Drug Administration issued an 'early communication' yesterday that they were "investigating a possible association between the use of Singulair and behavior/mood changes, suicidality (suicidal thinking and behavior) and suicide."

It is important to note that this 'early communication' is not any kind of alert or warning and that no link has yet been found between Singulair and suicide. Instead, as with all medicines, the FDA tries to trace back reports of problems that people have while they take a medicine to see if they are actually caused by the medicine or are just a coincidence. The report on Singulair should be done in about 9 months.

While your kids don't need to stop taking Singulair for their allergies or asthma, it is a good reminder to monitor them for any new symptoms or problems that they develop once they start taking Singulair or any other medicine. And then report those problems or side effects to your pediatrician and the FDA through the Medwatch Reporting System.

Related:
FDA Early Communication About an Ongoing Safety Review of Montelukast (Singulair)
Medwatch - Reporting Medication Side Effects
Allergies
Asthma